ATROVENT 250 UDVS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
01-04-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
IPRATROPIUM BROMIDE MONOHYDRATE
Available from:
B & S Healthcare
Dosage:
0.25 anhyd mg/ml
Pharmaceutical form:
Nebuliser Solution
Authorization date:
2007-06-29
Summary of Product characteristics
License
IRISH MEDICINES BOARD ACT 1995
MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998
(S.I. No.142 of 1998)
PPA1328/070/001
Case No: 2029758
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
B & S Healthcare
Unit 4, Bradfield Road, Ruislip, Middlesex, HA4 0NU, United Kingdom
an authorisation, subject to the provisions of the said Regulations, in respect of the product
Atrovent 250 UDVs 250 micrograms / 1 ml Nebuliser Solution
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 29/06/2007 until 28/06/2012.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
Irish Medicines Board
______________________________________________________________________________________________________________________
Date Printed 04/07/2007
CRN 2029758
page number: 1
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Atrovent 250 UDVs 250 micrograms / 1 ml Nebu
Read the complete document
